Healthcare Law Update: July 2019

Holland & Knight LLP
Contact

Holland & Knight LLP

CMS Regulation

District Court Strikes Down Rule Mandating Price Disclosure in DTC Pharmaceutical Advertisements

Charles A. Weiss

The U.S. Department of Health and Human Services (HHS), together with the Centers for Medicare & Medicaid Services (CMS), in May 2019 published a final rule requiring direct-to-consumer (DTC) television ads for prescription drugs to include a statement of the products' wholesale acquisition cost (WAC) in a specified format: "The list price for a [30-day supply of][typical course of treatment with][name of product] is [list price]. If you have health insurance that covers drugs, your cost may be different." The statement is not required if the disclosed WAC would be less than $35, or if the product is ineligible for Medicare/Medicaid reimbursement. Few (if any) drugs advertised on television would not be covered by the rule.

In June 2019, a group of industry participants filed suit against HHS and CMS in the District of Columbia, challenging the legality of the rule and seeking a stay of its mandate pending full resolution on the merits. They challenged the rule on two grounds: (1) The rule exceeds the agencies' authority under the Social Security Act, and (2) the rule violates the First Amendment as impermissible compelled speech. Moreover, they argued that the rule compels a false statement because a product's WAC is not a "list price" that translates into what patients — even uninsured patients — pay at the pharmacy counter.

In support of their first argument, the plaintiffs presented declarations from professors at the Kellogg School of Management at Northwestern University and the Yale School of Management which argued that when HHS formally announced in May 2018 that it was considering price disclosure requirements for DTC ads, HHS stated that it would look to the Food and Drug Administration (FDA) to consider inclusion of prices. However, the FDA has in the past taken the position that its enabling statute, the Food, Drug, and Cosmetic (FD&C) Act, does not authorize it to require price disclosure. Whether driven by the FDA's historical position regarding the scope of its own authority or for other reasons, the government instead based the DTC rule on CMS' general authority to promulgate regulations to promote the "efficient administration" of Medicare and Medicaid. The plaintiffs argued this foundation is too weak.

Most discussion of the DTC rule has concerned the plaintiffs' second argument that it amounts to "compelled speech" in the commercial context. The government argued for review under the relatively deferential Zauderer standard, after a 1985 Supreme Court case holding that a state could require certain fee disclosures in attorney advertising. In general terms, Zauderer provides that mandated disclosure of "purely factual and uncontroversial information" concerning issues such as price does not run afoul of the First Amendment so long as the requirements are not "unjustified" or "unduly burdensome." The plaintiffs disputed the government's reliance on Zauderer, arguing that the WAC price is not the price at which drugs are sold at retail, and is essentially unrelated to the price paid by the vast majority of consumers.

Rather than the deferentialZauderer standard, the plaintiffs relied on the familiar Central Hudson test after a 1980 Supreme Court decision that invalidated a ban on utility companies' promotion of electricity usage (intended to support conservation efforts in the 1970s), which generally applies to regulation of commercial speech. To pass muster under the Central Hudson standard, regulation of commercial speech must (i) directly advance a substantial government interest, and (ii) be narrowly tailored to achieve it. Here, the challengers argued that the rule will neither provide meaningful price information to consumers (because of the mismatch between WAC and the actual price paid at the pharmacy counter, especially for patients with insurance), nor will it rein in drugs costs borne by the Medicare and Medicaid programs. Moreover, the plaintiffs stated that there are other and better ways to communicate to patients what their actual costs are likely to be for the advertised drugs.

The government's opposition brief played into certain of the plaintiffs' arguments by defending the propriety of embarrassing pharmaceutical companies through compelling disclosure of oftentimes eye-popping WAC prices. For example, the government wrote that if manufacturers "are embarrassed by their excessive prices and thus lower them," that is an objective of the rule and is achieved in a constitutional manner. Similarly, said the government, by "increasing price transparency and exposing overly costly drugs to public scrutiny, the DTC rule helps to incentivize the manufacturers to reduce their list prices." In addressing the public interest, the government contended that the rule "will play an important role in combatting out-of-control prescription drug prices that are threatening the long-term viability of Medicare and Medicaid and that are unfairly draining the bank accounts of more Americans every day."

The plaintiffs' reply brief made the point that the government's brief showed that the DTC rule is more about grandstanding and scoring political points than providing consumers with actionable information about the likely out-of-pocket cost of a prescription for a drug they see advertised on television. They wrote that "HHS candidly admits that one of the Rule's key 'objectives' is to shock consumers and 'embarrass[]' manufacturers. It is designed to increase 'public scrutiny' on manufacturers by forcing them to display a 'list' price that is worlds apart from the actual price for most of the intended audience of consumers."

At oral argument on July 2, 2019, the court closely questioned both sides and inquired if it might finally resolve the case on the merits instead of ruling only on the plaintiffs' application for a stay. The court ruled in favor of the plaintiffs on July 8, striking down the rule on the eve of its effective date on statutory grounds while avoiding the First Amendment issues under the doctrine of "constitutional avoidance." Specifically, the court held that the Social Security Act's general grant of rulemaking authority to promulgate regulations necessary to "administration" of the Medicare and Medicaid programs did not suggest that Congress intended to authorize HHS and CMS to make rules directly regulating the conduct of "market actors that are not direct participants in the Medicare or Medicaid Programs" and that:

Pharmaceutical manufacturers are not health care providers, private plan carriers, or beneficiaries—each of whom plays a direct role in the public health insurance programs. They do not receive payment for their products from CMS. Their pricing decisions, of course, affect the cost of pharmaceutical benefits offered under the Medicare and Medicaid programs. But those decisions impact program costs in an indirect way. The plain statutory text simply does not support the notion—at least not in a way that is textually self-evident—that Congress intended for the Secretary to possess the far-reaching power to regulate the marketing of prescription drugs.

Elaborating on its reasoning, the court reviewed a number of provisions of the Social Security Act and noted the difference in scope between regulating program participants and reaching more broadly to the overall healthcare market:

What these provisions have in common is this: each contains a congressional directive that concerns the day-to-day running and operation of Medicare and Medicaid as public health insurance programs, and each is directed in some way to a program participant or the program itself. None authorize HHS, in the name of attempting to reduce the costs, to regulate the health care market itself or market actors that are not direct participants in the insurance programs.

The court also pointed to the absence of authority in the FD&C Act to promulgate rules mandating price disclosure, despite the comprehensive regulation of pharmaceutical advertising otherwise provided for therein: "Congress deliberately and precisely legislated in the area of drug marketing under the [FD&C Act]. Such purposeful action demonstrates that Congress knows how to speak on that subject when it wants to."

Having found that HHS lacked authority to promulgate the rule, the district court did not have to reach the First Amendment challenge or resolve other points of contention raised in the parties' respective submissions. The district court entered final judgment on the merits in favor of the plaintiffs. Accordingly, the government's next step, if it still wishes to defend the rule, will be to appeal or seek and receive express authority from Congress.

Enforcement

Bundled Medicare Items or Services Tainted by Kickback May Trigger FCA Liability

Kayla L. Pragid

In United States ex rel. Simpson v. Bayer Corp., No. 05-3895, 2019 WL 1772560 (D.N.J. Ap. 23, 2019), the district court determined that any item in a bundled Medicare claim that is tainted by a kickback or violation of any Medicare laws, regulations or program instructions could trigger liability under the False Claims Act (FCA) even where the government did not pay more for the claim based on the patient's receipt of the particular item or service.

The relator brought a qui tam action under the FCA whistleblower provision, alleging: (1) Bayer pharmaceuticals caused hospitals to submit false claims by improperly marketing off-label uses of Trasylol (a drug that was sometimes used to reduce bleeding during surgery) for uses that were not reasonable and necessary under Medicare's guidelines; and (2) Bayer paid illegal kickbacks to physicians to induce them into using the drug for the off-label purposes. In response, Bayer argued that, even if the hospital's use of Trasylol was not reasonable or necessary or the hospital over-utilized Trasylol due to illegal kickbacks, the Medicare claims were not false under the FCA as a matter of law because Trasylol was "bundled" with all other surgical expenses, rather than itemized on the bill such that the fixed cost claim amounts for the surgeries did not change based on whether Trasylol was or was not administered.

The court rejected Bayer's argument, emphasizing the difference between factual and legal falsities in the FCA context. A claim is factually false when the claimant misrepresents the goods or services it provided to the government. A claim is legally false when the claimant misrepresents (or misleadingly omits) "its compliance with a statutory, regulatory, or contractual requirement[s]." The relator contended the at-issue claims were legally false because the hospitals made express certifications to Medicare by signing certain standard Medicare forms — a Medicare Enrollment Application (form CMS-855A) and Medicare annual reports (form CMS-2552) — that were false. The Medicare Enrollment Application includes the following certification:

I agree to abide by the Medicare laws, regulations and program instructions. ... I understand that payment of a claim by Medicare is conditioned upon the claim and the underlying transaction complying with such laws, regulations, and program instructions (including, but not limited to, the Federal anti-kickback statute ...

Likewise, hospitals' annual reports to Medicare (form CMS-2552) include an acknowledgement that:

IF SERVICES IDENTIFIED IN THIS REPORT WERE PROVIDED OR PROCURED THROUGH THE PAYMENT DIRECTLY OR INDIRECTLY OF A KICKBACK OR WERE OTHERWISE ILLEGAL, CRIMINAL, CIVIL AND ADMINISTRATIVE ACTION, FINES AND OR IMPRISONMENT MAY RESULT.

The court held these certifications of compliance with the Anti-Kickback Statute (AKS) were false, as a matter of law, if the bundled claims submitted to Medicare included any items or services that resulted from an unlawful kickback. The court reasoned that "Congress expressly made AKS violations actionable under the FCA ... to strengthen whistleblower actions based on medical care kickbacks and to ensure that all claims resulting from illegal kickbacks are considered false claims for the purpose of civil action[s] under the FCA." Furthermore, even where a noncompliant claim did not cost the government more than a compliant claim, that payment of such a claim "does not mean the Government is indifferent to underlying compliance violations" because "[t]he Government does not get what it bargained for when a defendant is paid ... for services tainted by a kickback."

For these reasons, the court denied Bayer's motion for summary judgment and held that Bayer may be liable under the FCA for Medicare claims it submitted for surgical procedures in which the drug Trasylol was administered "regardless of whether the relevant requests for reimbursement were bundled rather than itemized, and regardless of whether the administration of Trasylol in these procedures affected the total amount of corresponding reimbursement."

Missing Hospice Certifications Were Material Grounds for FCA Violations

Nathan A. Adams IV

In United States ex rel. Lemon v. Nurses to Go Inc., No. 18-20326, 2019 WL 2004353 (5th Cir. May 7, 2019), the court of appeals reversed the district court's conclusion that the relators had alleged mere "laziness, bungled paperwork and mistakes that were corrected" on the part of several hospice organizations not material to Medicare reimbursement and, thus, not in violation of the FCA. The relators, former employees, alleged that the defendants failed to complete and maintain certifications and recertification for hospice patients; failed to complete and maintain physician narratives in support of certifications for hospice patients; allowed nonmedical personnel to complete certifications for hospice patients; allowed nonmedical personnel to complete physician narratives for hospice patients; failed to have required face-to-face encounters between physicians and patients; permitted nurses to conduct required face-to-face encounters with hospice patients instead of a physician or nurse practitioner; completed certifications after the time period required for completion; failed to write individualized plans of care; and billed for and provided services to deceased patients. The court observed that section 1395f(a)(7) of the Medicare statute lists a number of certifications that are "conditions of ... payment for" hospice services, and that "payment for services furnished" may be made "only if" the certification, face-to-face encounter and plan-of-care requirements are made. In addition, Medicare regulations for hospice services state that "to be covered," certifications regarding terminal illness must be completed. Therefore, the court found that defendants' alleged conduct violated conditions of payment and, as evidence that the government would deny payment if it knew of the defendants' false certifications, found that the HHS Office of Inspector General has previously taken enforcement action against hospice providers that have submitted bills for ineligible patients. Last, the court determined that the violations, as alleged, were not minor even though defendants argued that they billed for what they did and did not commit fraud.

Non-Owners of Company That Presents Fraudulent Claims May Still Be Liable Under FCA

Nathan A. Adams IV

In United States ex rel. Doe v. Heart Solution, P.C., 923 F. 3d 308 (3d Cir. 2019), the court of appeals ruled that individual employees with no ownership interest in a company that presents a fraudulent claim can still be liable under the FCA. The Patels, a husband and wife duo, pled guilty to separate but nearly identical criminal information charges for defrauding Medicare. The Patels falsely represented to Medicare that neurological testing was being supervised by a licensed neurologist. Ms. Patel argued that because she did not have any ownership interest in Mr. Patel's healthcare company, she had no duty to ensure that it employed a supervising neurologist. The court disagreed, holding that an ownership interest is not required for FCA liability. Collateral estoppel was another issue in the case. The court ruled that the defendant's healthcare company could not be collaterally estopped, based on a Medicare fraud conviction and plea colloquy, from contesting FCA liability or damages where the company was not charged with healthcare fraud, and its role in defrauding Medicare by submitting false reports about neurological testing was not actually litigated or determined by a final judgment in the criminal proceeding. In addition, Ms. Patel's admission that she submitted false claims to Medicare about the neurological testing at her husband's healthcare company, and that her husband's company and her company were paid roughly $1.18 million from Medicare for unsupervised neurological testing, did not collaterally estop her from denying liability or damages with regard to the government's common law claims for unjust enrichment, disgorgement of profits and payment by mistake of fact because the admissions left open the possibility that the defendant's husband and his company retained the entire benefit of the fraud. She was collaterally estopped from denying the falsity and knowledge elements of the government's FCA claims. The court would not allow Mr. Patel's unsworn statement that his company employed a supervising neurologist during certain years to create an issue of fact on summary judgment.

Billing for Absent Teaching Physician in Surgery Was Material Ground for FCA Violation

Nathan A. Adams IV

In United States ex rel. Wollman v. General Hosp. Corp., No. 1:15-cv-11890-ADB, 2019 WL 2501669 (D. Mass. June 17, 2019), the district court ruled that a relator's claims that a hospital wrongly billed the government for time patients spent in surgery without a teaching physician immediately available in the room were not "minor or insubstantial" billing rules, and, although "they may not be among the most central to the Medicare and Medicaid programs overall, they are sufficiently central to the payment scheme for concurrent and overlapping surgeries to have received congressional attention and expressions of concern over noncompliance." Specifically, the relator, a former treating anesthesiologist at the defendant hospital, alleged that teaching surgeons routinely left patients who were undergoing surgery alone with residents and fellows in order to conduct concurrently scheduled surgeries, and that they did so without identifying another qualified teaching physician who would be immediately available in the event of an emergency and without keeping proper records or obtaining the patients' informed consent. The relator also claimed that the practice resulted in patients being under anesthesia for extended, medically unnecessary periods. To receive Medicare payments for services performed by a teaching physician, the services must either be "personally furnished by a physician who is not a resident," or "furnished by a resident in the presence of a teaching physician," except in certain specified situations. 42 C.F.R. §§415.170, 415.172. When a teaching physician is not present during portions of the procedure that are not critical or key and is participating in another surgical procedure, he or she must arrange for another qualified surgeon to immediately assist the resident should the need arise. When submitting a claim for reimbursement, the hospital certifies compliance with these Medicare rules and regulations for payment.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Holland & Knight LLP | Attorney Advertising

Written by:

Holland & Knight LLP
Contact
more
less

Holland & Knight LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.